Pacer Advisors’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Pacer Advisors's DNLI Position: Q2 2026 in Review
Pacer Advisors opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 1,609 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #2085 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in DNLI as recently as Q2 2024.
Pacer Advisors first reported a position in DNLI in Q3 2020 and has held it in 6 quarters since. The position peaked at $139K in Q4 2020. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Pacer Advisors held 1,609 shares of Denali Therapeutics worth $41K as of Q2 2026.
- Denali Therapeutics was a new Pacer Advisors position in Q2 2026.
- Denali Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2085 holding.
- Pacer Advisors first reported a position in Denali Therapeutics in Q3 2020 and has held it in 6 quarters since.
- Pacer Advisors's Denali Therapeutics position peaked at $139K in Q4 2020.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.